Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netoglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | CDC25B | P30305 | 2/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netoglitazone SCHEMBL29434827 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29361540 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125596 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29355957 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL20125595 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL29355960 | 1.00 | FFAR1 (0.55) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| Netoglitazone SCHEMBL8877880 | 0.99 | FFAR1 (0.54) | FFAR1PPARAPTPN1PPARGPTPN2 | |
| SCHEMBL7514721 | 0.89 | PTPN1 (0.52) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL4239883 | 0.89 | MAOB (0.51) | FFAR1PPARAPTPN1PTPN2CDC25B | |
| SCHEMBL7634850 | 0.88 | FFAR1 (0.57) | FFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 877 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | claimed |
| US-20220170034-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE TECHNOLOGY, INC. | 2022-06-02 | — | — | US | claimed |
| EP-3999103-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | Inari Agriculture, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2021016043-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE, INC. (US) | 2021-01-28 | — | — | WO | claimed |
| US-20200121665-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-23 | — | — | US | claimed |
| US-20160128994-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-05-12 | — | — | US | claimed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| WO-2007127791-A2 | NEW PHARMACOLOGICAL METHOD FOR TREATMENT OF NEUROPATHIC PAIN | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2007-10-25 | — | — | US | claimed |
| EP-1248604-B1 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2006-11-29 | — | — | EP | claimed |
| US-6353009-B1 | TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | claimed |
| EP-0796618-B1 | Treatment and prophylaxis of pancreatitis | SANKYO CO (JP) | 2002-01-30 | — | — | EP | claimed |
| WO-2000041690-A9 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | UNIV CALIFORNIA (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1131310-A1 | CHRYSTALS OF 5- 6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-09-12 | — | — | EP | claimed |
| US-6150371-A | WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE | SANKYO COMPANY, LIMITED (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000041690-A1 | USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000031055-A1 | CHRYSTALS OF 5-[{6-(2-FLUOROBENZYL)OXY-2-NAPHTHYL}METHYL]-2,4-THIAZOLIDINEDIONE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-06-02 | — | — | WO | claimed |
| EP-0919232-A1 | Composition for use in the treatment and prevention of hyperuricemia | Sankyo Company Limited (JP) | 1999-06-02 | — | — | EP | claimed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | claimed |
| US-5594016-A | ANTIDIABETIC AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | PPARG, PPARA, CNR2 | PPARG 1/4885FFAR1 167/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.